We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collagen Deposition-Promoting Gene Linked to Cancer Metastasis

By LabMedica International staff writers
Posted on 07 Mar 2017
Cancer researchers have identified a gene that when active promotes the metastasis of breast cancer (BC) by increasing collagen deposition by breast cancer-associated mesenchymal stem/multipotent stromal cells.

The molecular mechanism underlying the increased collagen disposition was not known. More...
To correct this deficiency, investigators at the University of Michigan analyzed the activity of the collagen receptor discoidin domain receptor 2 (DDR2) gene, which is essential for stromal-BC communication. They looked at levels of ddr2 enzyme activity in cells at sites of BC metastasis as well as working with the slie line of mice, which had been genetically engineered to lack the DDR2 gene.

The investigators reported in the January 31, 2017, issue of the journal Cell Reports that in human BC metastasis, DDR2 was consistently upregulated in metastatic cancer cells and in multipotent mesenchymal stromal cells (MSCs). In MSCs isolated from human BC metastasis, DDR2 maintained a fibroblastic phenotype with collagen deposition and induced pathological activation of DDR2 signaling in BC cells.

Loss of DDR2 in MSCs impaired their ability to promote DDR2 phosphorylation in BC cells, as well as BC cell alignment, migration, and metastasis. Female ddr2-deficient mice homozygous for the slie mutation showed inefficient spontaneous BC metastasis.

“We discovered that DDR2 mediates the communication between mesenchymal stem cells and cancer cells,” said senior author Dr. Celina Kleer, professor of pathology at the University of Michigan. “When we inhibit this receptor in the mesenchymal stem cells, it tricks the cancer cells. The cells do not align, they do not migrate, and they do not metastasize efficiently. This suggests a possible therapeutic target. Our goal is to identify a way to interrupt breast cancer metastasis growth and invasiveness, either to prevent metastases from forming or to keep them at bay when they do develop. The microenvironment is a rich opportunity to better understand why cancer metastasizes and begin to attack that process.”


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.